Cedars-Sinai Cancer | Strategic Alliance Partners

April 15, 2024

Drs Camidge and Rimel spotlight Dr Rimel’s career journey and the work she does to expand medical care for transgender patients.

February 21, 2024

Anthony T. Nguyen, MD, PhD, discusses the role of concurrent chemotherapy with trimodal therapy in patients with muscle-invasive bladder cancer.

February 20, 2024

Jun Gong, MD, discusses the significance of the phase 3 EMBARK study of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

February 15, 2024

Anthony T. Nguyen, MD, PhD, discusses the methodology of trimodal therapy in patients with muscle-invasive bladder cancer.

February 07, 2024

Jun Gong, MD, discusses the current treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

January 29, 2024

Jun Gong, MD, discusses efforts to address unmet needs in metastatic hormone-sensitive prostate cancer.

December 08, 2023

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

November 30, 2023

State of Science Summit: Prostate/Bladder Cancer - Chaired by Edwin M. Posadas, MD

August 22, 2023

Megan Hitchins, PhD, discusses the rationale for conducting an analysis on the prevalence of high-risk constitutional MLH1 methylation in patients with early-onset colorectal cancer and endometrial cancer.

August 15, 2023

Megan Hitchins, PhD, discusses results from an analysis on the prevalence of high-risk constitutional MLH1 methylation in early-onset colorectal and endometrial cancers displaying mismatch repair deficiency.

August 09, 2023

Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.

August 09, 2023

Dr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.

August 09, 2023

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

July 25, 2023

New research from Cedars-Sinai Cancer investigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common cause of hereditary colorectal and endometrial cancers.

July 18, 2023

Cedars-Sinai Cancer investigators elucidate how this process allows bladder tumors to evade the immune system but also makes them vulnerable to a common treatment.

July 07, 2023

Yuan Yuan, MD, PhD, discusses ongoing investigations at Cedars-Sinai of treatment de-escalation in patients with early-stage triple-negative breast cancer according to their pathological response.

June 30, 2023

Joshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.

June 30, 2023

David R. Oveisi, MD, discusses the evolution and potential role of bispecific antibodies in multiple myeloma, and presents several areas of unmet need regarding their use in this space.

June 27, 2023

Yuan Yuan, MD, PhD, discusses the OptimICE-pCR trial and other ongoing clinical trials in breast cancer being conducted at Cedars-Sinai, and expands on the role of CDK4/6 inhibitors and other novel treatment strategies for patients with hormone receptor-positive breast cancer.

June 21, 2023

Physicians at Cedars-Sinai Cancer are using a unique chemotherapy delivery system that offers hope to colorectal cancer patients whose disease has spread and who now have inoperable liver tumors.